2:40 PM
Jul 10, 2018
 |  BC Innovations  |  Distillery Therapeutics



Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a viability assay in fusion-positive and five fusion-negative rhabdomyosarcoma cell lines, identified 35 compounds, including the dual MAP2K1/MAP2K2 inhibitor Mekinist, as...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >